Skip to main content
European Commission logo print header

Commercial feasibility of microbial therapy

Objetivo

Our body is colonized by complex microbial communities (our microbiome) that are most abundant in the intestinal tract where they contribute significantly to our health and disease. It has been established that aberrations in our microbiome are of particular importance in obesity, type 2 diabetes and metabolic syndrome, rapidly growing diseases with a drug market volume of over 5 B$ per year. We have discovered in the ERC project Microbes Inside that a particular bacterium is able to modify the intestinal microbiome and may be used to develop a new approach to treat these and other metabolic diseases. The Proof of Concept project ACOM aims to confirm the commercial and technological feasibility of this approach, consolidate and expand our IP position, and develop a product development plan. These form the elements of a business plan that is expected to result in establishing a spin out company (ACOM).

Convocatoria de propuestas

ERC-2013-PoC
Consulte otros proyectos de esta convocatoria

Institución de acogida

WAGENINGEN UNIVERSITY
Aportación de la UE
€ 142 000,00
Dirección
DROEVENDAALSESTEEG 4
6708 PB Wageningen
Países Bajos

Ver en el mapa

Región
Oost-Nederland Gelderland Veluwe
Tipo de actividad
Higher or Secondary Education Establishments
Contacto administrativo
Tom Bessems (Mr.)
Enlaces
Coste total
Sin datos

Beneficiarios (1)